We have reviewed the evidence herein that LTB4 biosynthesis is activated in intraocular inflammatory diseases, VEGF exists in uveitic conditions and in animal models of uveitis and targeting both pathways in combination therapy may prevent further tissue damage and disease complications. The gene discussed is VEGFA; the disease is uveitis.